George Eliades - Jazz Pharmaceuticals Senior Officer
| JAZZ Stock | USD 108.62 0.37 0.34% |
Executive
George Eliades is Senior Officer of Jazz Pharmaceuticals PLC
| Age | 53 |
| Address | Waterloo Exchange, Dublin, Ireland, D04 E5W7 |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0407 % which means that it generated a profit of $0.0407 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0941 %, meaning that it created $0.0941 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.5 B in 2024, despite the fact that Net Tangible Assets are likely to grow to (3.7 B).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kennett Sprogoe | Ascendis Pharma AS | 45 | |
| Chris Walsh | Denali Therapeutics | N/A | |
| Liz Gosen | Legend BiotechCorp | N/A | |
| Adam Townsend | Apellis Pharmaceuticals | 46 | |
| Jason Adair | Liquidia Technologies | 50 | |
| Kevin Smyth | Bio Techne Corp | N/A | |
| Dana Aftab | Exelixis | 61 | |
| William MD | Exelixis | N/A | |
| Karen Massey | argenx NV ADR | 45 | |
| David Clair | Bio Techne Corp | N/A | |
| Katie Peng | Denali Therapeutics | N/A | |
| Traci McCarty | Biomarin Pharmaceutical | N/A | |
| Elvia Cowan | VaxcyteInc | 51 | |
| Jeffrey Ajer | Biomarin Pharmaceutical | 62 | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Anthony Casciano | Viridian Therapeutics | 47 | |
| Cindy Dunkle | Denali Therapeutics | N/A | |
| Abha Bommireddi | Protagonist Therapeutics | N/A | |
| Tolga MBA | Alnylam Pharmaceuticals | 51 | |
| Arjen MSc | argenx NV ADR | 39 | |
Management Performance
| Return On Equity | 0.0941 | ||||
| Return On Asset | 0.0407 |
Jazz Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Finbar Larkin, VP Operations | ||
| George Eliades, Senior Officer | ||
| Daniel Swisher, NonExecutive Employee | ||
| Patricia Carr, Senior Officer | ||
| Jed MD, Senior Medicine | ||
| Renee Gala, President COO | ||
| Andrea Flynn, VP Relations | ||
| Robert MD, Executive Development | ||
| Philip Johnson, Executive CFO | ||
| Rene Gal, President COO | ||
| Heidi Manna, Executive Officer | ||
| Neena JD, Executive Officer | ||
| Samantha Pearce, Senior International | ||
| Bruce Cozadd, Co-Founder, Executive Chairman and CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0941 | ||||
| Return On Asset | 0.0407 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 10.81 B | ||||
| Shares Outstanding | 63.04 M | ||||
| Shares Owned By Insiders | 2.77 % | ||||
| Shares Owned By Institutions | 97.19 % | ||||
| Number Of Shares Shorted | 3.6 M | ||||
| Price To Earning | 35.18 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Jazz Pharmaceuticals PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.757 | Earnings Share 4.83 | Revenue Per Share 60.956 | Quarterly Revenue Growth 0.01 | Return On Assets 0.0407 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.